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Several studies have shown that adherence to growth hormone therapy (GHT) is not
optimal. There are several reasons why patients may not fully adhere to their treatment
regimen and this may have implications on treatment success, patient outcomes and
healthcare spending and resourcing. A change in healthcare practices, from a physician
paternalistic to a more patient autonomous approach to healthcare, has encouraged a
greater onus on a shared decision-making (SDM) process whereby patients are actively
encouraged to participate in their own healthcare decisions. There is growing evidence
to suggest that SDM may facilitate patient adherence to GHT. Improved adherence to
therapy in this way may consequently positively impact treatment outcomes for patients.
Whilst SDM is widely regarded as a healthcare imperative, there is little guidance on
how it should be best implemented. Despite this, there are many opportunities for the
implementation of SDM during the treatment journey of a patient with a GH-related
disorder. Barriers to the successful practice of SDM within the clinic may include poor
patient education surrounding their condition and treatment options, limited healthcare
professional time, lack of support from clinics to use SDM, and healthcare resourcing
restrictions. Here we discuss the opportunities for the implementation of SDM and the
barriers that challenge its effective use within the clinic. We also review some of the
potential solutions to overcome these challenges that may prove key to effective patient
participation in treatment decisions. Encouraging a sense of empowerment for patients
will ultimately enhance treatment adherence and improve clinical outcomes in GHT.
Keywords: growth hormone therapy, delivery device, shared decision-making, patient autonomy, treatment
adherences
GROWTH HORMONE THERAPY (GHT) AND ADHERENCE TO
TREATMENT IS NOT OPTIMAL
The treatment success of many chronic conditions including those associated with the need for
long-term GHT, may be dependent upon several factors including patient characteristics, therapy
area challenges, treatment access, and healthcare provisions. These factors also vary widely in
different countries. One key contributor to treatment success however is patient adherence to
their treatment regimen and commitment to long-term therapy. The World Health Organization
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defines treatment adherence as “the extent to which a person’s
behaviour—takingmedication, following a diet, and/or executing
lifestyle changes—corresponds with agreed recommendation
from a healthcare provider” (1). In the context of GHT, this
may involve patient adherence with respect to timing of the
growth hormone (GH) dose, GH dose frequency, and method of
administration (device instructions) (2).
The definition of adherence however may also be extended
to reflect an active and continuous process that comprises more
than just treatment posology and dose frequency, but rather
adherence to a whole treatment plan as born out of a decision
process between both a patient and their clinician. It is also
important to consider the notion of persistence to treatment.
Persistence may be defined as “the duration of time from
initiation to discontinuation of therapy” (2). When considering
GHT, a patient’s treatment journey may be lengthy and both
patients and their families must commit to a long-term process.
Clinical outcomes will therefore not only be impacted by patient
adherence to their treatment regimen, but also by how well
they persist with their treatment over a long period. Thus, it is
important to clearly distinguish between these two definitions
when considering clinical outcomes and patient commitment to
their treatment plan.
When considering patient adherence and persistence to GHT,
one might place more importance on what happens when
patients do not adhere or persist with their treatment regimens.
Non-adherence to therapy is of considerable concern and may
have implications for treatment outcomes (2, 3). A report in
2003 by the World Health Organization reported that treatment
adherence in patients with chronic diseases is as low as∼50% (1).
In the case of GHT specifically, non-adherence has been shown to
impact linear growth and growth velocity (4, 5). Poor adherence
to therapy may also ultimately incur increased healthcare service
utilisation and greater healthcare spending (5–7).
There are a number of studies that demonstrate that
adherence to GHT is not optimal, however the exact rates of
non-adherence reported differ considerably (5, 8–14). A study by
Oyarzabal et al. reported “excellent” compliance in 74.0% of the
473 patients surveyed, while a study by Rosenfeld et al., reported
a similar proportion (64–77%) of non-compliance following
their survey of GHT patients. Variation in definitions of non-
adherence (fixed cut-offs or any action that interferes with an
individual’s treatment plan) (15, 16), patient populations and
study methodology may contribute to these differences. Despite
this, there appears to be a consensus that adherence to GHT could
be improved.
Adherence to GHT may be monitored in several
ways including prescription monitoring, patient/parent
questionnaires/interviews, and biomarker testing (17, 18).
Monitoring of issued, renewed or encashed GHT prescriptions
offers perhaps the most objective measure of adherence,
however it does not provide details regarding specific days of
treatment missed or timing inconsistencies, but rather only a
gross measure of patient adherence (19). Conversely, patient
questionnaires and interviews may offer a more thorough
account of patient non-adherence but are often limited by the
potential for misrepresentation of information, given patients
difficulty to recall past events or fear of disappointing the doctor
(20). Urinary GH levels (21, 22) or biomarker monitoring
of serum insulin-like growth factor 1 (IGF-1) (23, 24), may
also be an option to monitor adherence. However, challenges
associated with timing of monitoring, data variation, and assay
variability/reliability make these methods difficult to implement
effectively and accurately (20). IGF-1 monitoring is yet to be
validated as a biomarker for adherence given its uncertainty as
to whether low levels represent poor adherence, low sensitivity
to GHT or other factors (24). Finally, injection devices with
incorporated electronic technologies capable of monitoring
and recording information on injections can be of assistance,
if they are accepted and used by patients and their caregivers
(25). Choosing a suitable means by which to monitor adherence
will ultimately be driven by low-cost, user-friendliness, and
practicality of application (20, 26).
There are many reasons why patients may not fully adhere
to their GHT regimen and may be broadly categorised into
treatment-specific, convenience, cognitive, and personal factors.
Treatment-specific factors may include the appearance of
unwanted side effects, apparent ineffectiveness of medication,
and access to treatment. Convenience challenges including
the logistics of GH administration, cold chain preservation,
travel, and difficulties with the dosing regimen may also
impact adherence to treatment. Cognitive factors may include
forgetfulness or poor education regarding why treatment
is necessary, while personal factors including patient-doctor
relationships, fear of needles, poor support, social pressure,
and denial may also contribute to non-adherence in patients
(14, 17, 27). A study by Bagnasco et al., in children and
adolescents receiving GHT in 46 paediatric centres across Italy,
found that the most frequently reported reasons for missing GH
doses were being away from home, forgetfulness, not feeling
well and pain (28). Finally, adherence to GHT may also be
influenced by whether GHT is self-injected by the patient
or administered by their parent/caregiver. Available data are
currently somewhat conflicting and more studies are needed to
investigate how patient or parent-led administration of GHTmay
impact adherence rates and ultimately treatment outcomes for
patients (9, 13, 28, 29). Importantly, consideration of adherence
as an “all or none” process may be too simplistic; the causes
of non-adherence may not always be predictable, nor may they
always be modifiable. There will most likely be a time, place or
situation-dependent variable to some of these factors, meaning
that overall, the concept of adherence is highly complex.
Understanding the ways in which patients may be better
encouraged to actively participate in their treatment journey
however, may serve to promote patient engagement and avoid
non-adherence in the first instance.
INTRODUCTION TO SHARED
DECISION-MAKING (SDM)
SDM may be defined as “an approach where clinicians and
patients share the best available evidence when faced with the
task of making decisions, and where patients are supported
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to consider options, to achieve informed preferences” (30).
The concept of SDM was first established in 1982 (31) and
originates predominantly from the notion of patient-centred care
(32) and a rebalance of the onus of decision-making between
clinician and patient. This is accompanied by a switch from
a focus on beneficence to a focus on patient autonomy and
supports a culture of active patient participation in decisions
to undertake therapy and their involvement in the details
of their treatment regimen (33, 34). Beneficence and non-
maleficence refer to a paternalistic approach whereby patient
interests are maintained, if need be, without patient participation
(35). Patient autonomy however upholds a patient’s right to
make decisions regarding their medical care without the undue
influence of their healthcare provider (30). While extreme ends
of a physician paternalistic/patient autonomous spectrum are
subject to criticism, establishing a balance between the two
may well serve to satisfy the best interest of the patient.
Indeed, SDM offers a means by which this balance can be
achieved and encourages an active participation of patients in
their own healthcare in partnership with their doctor (36).
Current guidelines from the National Institute for Health and
Care Excellence (NICE) and the position statement of British
Society for Paediatric Endocrinology and Diabetes (BSPED)
on the choice of delivery device for GH prescribing (37),
discuss the need for implementation of SDM in medical practice
and detail the steps doctors should take to implement active
patient involvement in their treatment (38). In addition, there
is growing evidence that SDM improves patient adherence and
treatment outcomes in several therapy areas, not limited to GHT
(28, 39–43).
CHALLENGES AND BENEFITS OF
IMPLEMENTING SDM IN GH DISORDERS
When considering SDM in the context of GH disorders, one
must consider the unique challenges that a predominantly
paediatric population of patients encounter. The notion of a
balance between physician paternalistic and patient autonomous
healthcare decisions is further complicated by the presence of
a patient’s parent/guardian as a third party who may wish to
participate in SDM. Some parents do not wish to be involved
in a SDM process and prefer a wholly paternalistic approach
by the clinician, while others wish to take an active role in the
decision-making process (44). SDM cannot therefore be a “one
size fits all” paradigm that may be applied in all situations. Rather
a careful consideration must be made of the opportunities for
SDM and the benefits this may have for both parent and patient.
Very young patients are unable to make treatment decisions
themselves and as such, parent preferences will likely determine
treatment decisions for the patient. As patients get older, their
involvement in the decision-making process will likely increase
and the practice of SDM should again be reviewed and adapted to
best suit their needs and treatment goals. Capturing both patient
and parent needs as part of this decision-making process will
encourage involvement in the treatment journey and positively
impact adherence to GHT as a result.
While the addition of parents or caregivers to the
patient/doctor dyad may prove challenging to manage, the
implementation of effective SDM may help patients and/or
parents to understand the importance of not missing doses
and the overall value of GHT. Adherence to GHT may be
affected by an underestimation of the consequences of missed
GH injections. In a study by Rosenfeld and Bakker, negative
influencers of adherence to GHT included a perception that
missed GHT doses did not have serious implications (13). While
missed insulin injections for patients with type-1 diabetes may
have both a serious and almost immediate impact on the patient,
patients who miss GHT injections may not notice any immediate
changes and may associate their GHT with a lack of effectiveness
(17, 45). While research has confirmed a correlation between
poor adherence to GHT and sub-optimal patient outcomes (5),
there remains a need to educate patients and/or parents in the
importance of regular GHT dosing and the consequences should
injections be missed.
There may also be a lack of appreciation, among patients
and/or parents, of the benefits of GHT beyond just increased
height. Whilst height velocity/linear growth are the most
commonly assessed measures of treatment success in prepubertal
patients, the benefits of GHT extend beyond improved
growth. GHT is known to have roles in body composition,
lipid metabolism, androgen action, myocardial function, and
cardiovascular health, as well as, improved quality-of-life
perception (46). Benefits of GHT in patients with GH-related
disorders other than GH deficiency (GHD) have also been
demonstrated (47–57). While improvement in adult height
is widely considered the main motivation for treatment in
children born small for gestational age (SGA), GHT is
associated with improved body composition, blood pressure,
lipid metabolism and reduced fat mass (52, 53). Improved
psychosocial functioning, quality of life, and intelligence are
also noted benefits of GHT in children born SGA (54, 55).
Similarly, in addition to increased final height, GHT has also
been associated with improvements in bone age and body
composition in patients with Noonan syndrome (51) and
improvements in lean body mass and reduced adiposity in
Turner’s syndrome (50). Finally, in patients with Prader-Willi
syndrome, improved visuospatial functioning, cognition, and
motor activity have been reported following treatment with GHT
(47, 56, 57). Awareness of the effects of GHT, beyond just
linear growth may thus serve to positively influence adherence
to GHT given the wider-reaching health benefits afforded to
patients (58).
Considering the variety of potential benefits afforded by GHT
and the specificities of its effect in different growth-related
disorders, it is vital that SDM is appropriately tailored to the
specific GH disorder being treated. Patients/parents must be
adequately educated in the potential benefits of GHT, such
that expectations of therapy can be accordingly managed. SDM
will thus support patient/parent education and encourage a
discussion of the wider benefits of GHT, specific to the patient’s
diagnosis. In conjunction with this, awareness of the quality
of evidence collected for certain patient-reported outcomes
(as commonly assessed with small-scale qualitative patient
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surveys/interviews, observational studies etc.) must also guide
SDM appropriately such that doctors may be entirely transparent
in their disease education.
SDM may go some way to address these knowledge gaps
around missed doses and the wider benefits of GHT by
encouraging patients to take an active and informed role in their
therapy. Opportunities for SDM during a patient’s treatment
journey include the decision to begin treatment, which GH
delivery device to use, if and how to self-monitor adherence and
growth progress, goal-setting, when to review treatment plans
following transition to adolescence and whether to continue or
terminate treatment. Opportunities to facilitate SDM at every
stage may not be possible, however the goal of SDM is not
necessarily to allow patients to dictate every aspect of their
treatment plan but rather take an active role in their own care
and in doing so encourage a greater “ownership” and satisfaction
with their treatment.
In line with the notion that SDM cannot be arbitrarily
implemented in every case, country-specific variations in practice
of SDM also need to be considered. For example, limited access
to certain treatment devices in some countries, as dictated by
cost restrictions or regulatory approvals, may mean there is little
room for SDM in the context of device choice compared with
the options that may be available to patients in other healthcare
systems with greater resources. Despite this, SDM is still crucial
in other points of a patient’s treatment journey, including patient
goal setting, motivations, and commitment to therapy. In Japan,
more importance is placed on within-family discussions than on
prolonged discussions with the doctor, encouraging the active
participation of family elders when making decisions regarding
treatment strategies (39). In other healthcare settings, including
those in the United Kingdom (UK), clinician time may be a
barrier to SDM given challenges to staff resource and predefined
consultations times (59). In the UK especially, the role of
specialist endocrine nurses and/or advanced nurse practitioners
as a support to a patient’s journey with GHT is of crucial
importance andwill offer the counselling, training, and education
that is required when patients first make the decision to undergo
GHT (60, 61). Finally, in other countries including Italy, there is
a need for a standardised and accredited process for the effective
implementation of SDM, to allow for a patient-specific care
plan whereby patients are appropriately educated about their
condition and the treatment options available such that treatment
adherence may be encouraged (28).
Defining a prescriptive model of SDM may therefore be
limiting. However, a form of SDM based on specific cases,
cultures, and healthcare system resourcing may prove to be
of greater utility. Below, we discuss some of the opportunities
for SDM during a patient’s treatment journey in more
detail.
SDM and the Decision to Start GHT
When considering SDM during a patient’s treatment journey, it
must be recognised that the decision to initiate therapy is likely to
be the first opportunity where it can be implemented. For GHT,
as with most medical strategies, there may be more than one
potential treatment path including delaying treatment initiation
or even not pursuing treatment at all (32). Each path will be
associated with varying therapeutic impact and side effects. It is
therefore critical for doctors to work with patients and/or parents
to help them understand their personal goals and preferences so
that they come to an informed and shared decision regarding
whether to begin treatment or not (32). In some healthcare
settings, this decision may also be driven, or at least influenced by
the cost of therapy (particularly when considering the long-term
nature of this treatment). SDMmay therefore be adjusted so as to
support consideration of a patient’s therapy options, within the
confines of a specific healthcare costing system.
Following initiation of GHT, patients are likely to remain
on their treatment regimen for many years (62), during which
time their preferences, motivations, and support structures are
likely to change significantly (17). As such, fully engaging
patients during their initial treatment decisions may prove
vital in nurturing patient “buy-in” further down the line.
Values clarification and preference elicitation exercises may
be particularly useful for early treatment decisions. Values
clarification encourages patients to consider those aspects of the
treatment option that are most and least important to them
while preference elicitation may encourage patients to consider
which of their options are most favoured, and conversely, least
favoured (63).
Finally, the decision to begin GHT may be a crucial point
at which to introduce SDM to set a precedent for a patient’s
involvement and engagement in their own subsequent treatment
plan. Patients may be unaware that they have a role to play in
decisions about their medical care (64, 65). While some may
not wish to be fully involved in the process of SDM, reassuring
patients that the decision to begin GHT is theirs and that they
have several options available to them, may help to garner patient
engagement with their healthcare plan and to introduce them to
the options that are available.
SDM and Selection of GH Injection Device
(A Typical Example)
The decision regarding which injection device to use is another
example of a stage during treatment that may be aided by the
active participation of both patient/parent and doctor to decide
on the most appropriate treatment choice. Historically, doctors
and nursing staffmade the choice of device type on behalf of their
patient, however patients are now encouraged to participate in
the process of device choice prior to treatment. Indeed, current
NICE guidelines state that “the choice of product should be
made on an individual basis after informed discussion between
the responsible clinician and the patient and/or their carer and
the advantages and disadvantages of the products available,
taking into consideration therapeutic need and the likelihood of
adherence to treatment” (62).
Likewise, the position statement of the BSPED on the
Choice of Delivery Device for Growth Hormone Prescribing,
recommends against “automatic substitution (dispensing one
brand instead of another equivalent or interchangeable brand)
by professionals other than the prescribing team, without
consultation with the hospital consultant managing the growth
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disorder” (37). Patient choice will thus most likely feature in this
consultation with the clinician when considering device change.
Whilst there is little evidence to predict which factors may most
likely drive patient device selection (12), there is growing opinion
that injection pen devices that increase the convenience of GH
administration are favoured by patients and may subsequently
go some way to improve adherence to treatment (66). In a
web-based survey assessing the impact of storage flexibility on
the daily life of patients and caregivers administering GH, 86%
of respondents who currently used a refrigerator-only product
stated that they would “prefer” or “strongly prefer” to use a
storage-flexible product. In the same survey, the proportion
of respondents who reported never missing an injection was
significantly greater for respondents using a storage-flexible
product (76%) compared with those using a refrigeration-only
product (57% p < 0.05) (67).
A study by Gau et al. reported that patient involvement in
device selection may improve adherence beyond the influence of
device features (39). This longitudinal group comparison study
of 46 patients with GHD investigated the influence of patient
choice on adherence to, and the therapeutic effects of GHT
over 3 years, using a questionnaire survey. Eighteen participants
were not given choice of device and assigned to a specific GH
device whilst the remaining 28 were given device choice (n =
13 of which chose the same device as the first group). Patient
choice improved adherence to GHT and resulted in improved
therapeutic effects (linear growth and IGF-1 levels) compared
with those patients who received no opportunity for device
choice, even for those patients who chose the same device
as patients with no choice. This study suggests that involving
patients in the process of device choice can improve adherence
to GHT and patient outcomes, independent of the device
features (39).
As discussed previously, the cost of GHT devices may also
be an important factor when making decisions and may be
considered during SDM. Limitations due to healthcare budgets
do not prevent the successful implementation of SDM to choose
the most appropriate device out of those that are available. Even
in cases where only one device may be available, this may still
be facilitated by SDM, as there are multiple factors that are still
appropriate to discuss with patients, including implementing the
device into daily routine and monitoring of adherence. Finally,
patient satisfaction of device may still drive device choice, rather
than cost. Meinhardt et al. reported that patients attribute a high
monetary value to specific device features that will enhance their
treatment experience and together suggest a willingness to pay
for such devices, that supersedes cost considerations (68).
Overall, while device features may have a considerable
impact on patient adherence, for patients in a country where
device features cannot be chosen (e.g., because of limited
access or marketing authorisation), it is still possible to have
acceptable treatment outcomes with a potentially “sub-optimal”
GH delivery device. In such situations, patient commitment
to their treatment regimen is crucial. Indeed, the notion of
improved ownership of treatment may begin with an active
involvement of patients when choosing their device such that
the process of taking responsibility for treatment decisions
actively encourages adherence and satisfaction. In summary,
SDM, whether implemented at device choice, or at other points of
a patient journey, appears to encourage a patient empowerment
in their own treatment regimen with a potential for greater
commitment to long-term treatment.
SDM and the Transition From Paediatric to
Adolescent/Young Adult Care
Transitionmay be defined as the “purposeful, plannedmovement
of adolescents with chronic medical conditions from child-
centred to adult-oriented health care” (69). However, in a number
of chronic conditions, including GH disorders, a large proportion
of patients terminate their therapy during their transition from
paediatric to adolescent/young adult care (70). In a study of UK
patients with congenital adrenal hyperplasia diagnosed during
the neonatal period, only 10% of patients continued onto
treatment in adult specialist endocrine centres (71). Reasons for
termination of treatment may include insufficient knowledge
of the treatment options available, a knowledge gap in the
disease process and the benefits of GHT into adulthood, patient
unwillingness to continue with their treatment regimen and
patient hesitation to engage with a new healthcare team as
part of their transition (70). Additionally, the cost of continued
treatment may further influence a patient’s decision to continue
treatment into adulthood.
The effects of GHT vary widely depending on what stage
of development it is administered. GHT in children normalises
linear growth and helps patients achieve adult height within
their genetic target range (70). In contrast, when continued into
adolescence and adulthood in the case of persistent GHD, GHT
helps to promote lean body mass, muscle strength and maintain
metabolism and lipid profile (72). For this reason, the transition
stage during a patient’s treatment journey is an important
opportunity for re-evaluation, review, and importantly, for SDM.
Transition into adolescence considered from a medical
perspective requires a re-evaluation of the patient need for GHT,
assessment of the potential for dose adjustments and review of
the current treatment regimen (72). However, in addition to
these considerations, the psychological, social, and educational
needs of transitioning patients with chronic endocrine conditions
must also be carefully considered (73, 74). Optimising adolescent
transition such that patients garner a desire for their own
autonomy (and indeed that parents relinquish that autonomy)
may prove challenging (75). A position statement of the
Canadian Paediatric Society recommends that preparation for
transition should begin early in patients to more smoothly
accommodate the transition process. While paediatric care is
very much family-focused and patient parents/caregivers play
a predominant role in treatment decisions as the first point
of contact with the doctor, adult care is patient-focused and
requires an autonomous approach in the absence of many
interdisciplinary resources (76). Gradually increasing patient
responsibility and education as patients get older will be best
supported with SDM and encourage a collaborative effort
between paediatric and adult endocrinologists, the patient and
their family (76).
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BARRIERS TO THE IMPLEMENTATION OF
SDM
There are many barriers that may hinder the effective
implementation of authentic SDM and may be categorised
according to patient/parent-related barriers, healthcare
professional-related barriers and healthcare system-related
barriers (Figure 1). Understanding the challenges to SDM will
serve to better inform the practice of its implementation and to
increase awareness of some of the obstacles to overcome.
Patient/Parent-Related Barriers
Poor educational backgroundmay be a key barrier to the effective
implementation of SDM. Authentic, patient-centred decision-
making can only be achieved with an appropriate level of
knowledge relating to the condition to be treated, the treatment
options available and the importance of treating the condition.
Patients may feel overwhelmed by a large volume of material
detailing their treatment options. Not understanding why long-
term treatment is necessary, or which device to choose may also
serve to compromise authentic SDM. Moreover, this educational
need should be applied to a patient’s family; where patients may
be too young to make a decision, the responsibility will fall with
their parents/caregiver. There is somewhat conflicting evidence
regarding whether parent education may have implications on
patient adherence to their GHT. While there are some reports
of no correlation between the level of parent education and
adherence in patients (14), Rosenfeld et al., found that parents
of highly GHT-compliant children had a lower education level
(13). Conversely, another study noted a significant correlation
between a GHT patient’s father’s educational level and adherence
to their GHT (77). Whilst the data may not be consistent,
patient/parent educationmay still be a crucial barrier to authentic
SDM, engagement with, and ultimately adherence to GHT.
In addition, patient/parent-related barriers may include
challenges that arise from an expectation of the roles of a
doctor/patient relationship (36). Discrepancies between these
expectations (some patients like to be told which decision is
right for them given the expertise of the doctor) may make
authentic SDM implementation difficult. Moreover, cultural,
and family-determined preferences may drive some of these
expectations and values. Indeed, in the context of a patient/doctor
relationship, a study by Suurmond and Seeleman, noted that
differing values regarding health and illness, role expectations
and pre-established prejudices may compromise authentic SDM
implementation (78). Similarly, patterns of parental preference
when deciding their children’s treatment decisions may further
complicate authentic SDM. A study by Singh et al. reported that
parents may place greater emphasis on different factors when
considering their child’s GHT. While the greatest proportion
(36%) of the group promoted a risk-conscious approach to
decision-making, others preferred a child-focused, cost-focused
or device ease-of-use oriented preference (79). Additionally, in
a survey of 69 parents with children treated with GHT, 79% of
the group reflected that support from other parents and their
doctor would be welcomed when considering GHT for their
FIGURE 1 | Barriers to the implementation of SDM. SDM, shared decision-making.
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children (80). Recognising parent preferences is thus crucial
to effective SDM. Parent-specific decision drivers and anxieties
about their children’s treatment may represent a significant
barrier to effective SDM (79).
A study that investigated the incidence of GHT in children
with idiopathic short stature, based on files collected at a
tertiary paediatric medical centre in Israel, reported that boys
accounted for a significantly larger proportion (65.8%) of the
study group despite no significant differences between sexes with
respect to age, height, body mass index or pubertal status. The
similar characteristics of both groups would suggest there is no
medically-determined reason for differences in GHT between
sexes. However, the male predominance to receive GHT may
reflect a family preference to treat boys with short stature more
commonly than girls (81). Similar gender bias has also been
reported in the United States (82) and Australia (83). While these
studies need to be accompanied by amore thorough investigation
of the psychological aspects of decisions to begin therapy, these
data may implicate gender-based preferences of families as a
barrier to authentic SDM given the possibility of pre-determined
attitudes toward GHT.
Finally, in a study exploring patient-doctor interviews and
perceptions of SDM, a lack of clarity of the concept of
SDM was noted with patients regarding who would make
the “final” decision. Confusion surrounding the role of SDM
and the respective roles of the patient and doctor led to
uncertain/tentative decisions from patients (84).
While evidence for these patient/parent-related barriers is
largely derived from only qualitative patient surveys, there are
commonly repeated references to outcomes that indicate that a
lack of patient/parent education and pre-determined attitudes
regarding GHT’s value are crucial barriers to effective SDM.
Healthcare Professional-Related Barriers
Several studies have also investigated healthcare professional-
related barriers that may hinder the effective implementation of
SDM (78, 84–86). Limited healthcare professional time is perhaps
the most commonly cited barrier and may be accompanied by a
challenging window of opportunity in which to build an adequate
patient-doctor relationship and authentically implement SDM
(85). Contact time with patients and family is critical for SDM,
however limited resources may be an obstacle to this. While
there is a great deal of literature identifying time as a major
concern for SDM (85), more recent evidence to evaluate the time
needed for effective SDM is somewhat conflicting. Two studies
trialling SDM initiatives for patients did not report increased
consultation times compared with consultation without SDM,
suggesting that time need not be a barrier to patient
choice (87, 88).
Other cited barriers related to healthcare professionals may
include their attitudes to SDM, perceived usefulness of its
implementation within the clinic, lack of sufficient information,
and self-confidence to implement it in practice, and cultural
differences (85, 86). Some healthcare professionals have also
cited that SDM may not be applicable given patient character
or clinical situation and may suggest a degree of doctor a priori
screening of the eligibility of SDM in a particular situation.
The potential for misunderstanding of patient needs/desire
for SDM thus makes this a concern that must be overcome
(89). Additionally, a report by Cuttler and Silvers (90) noted
that primary care of GHT is inconsistent given that doctors
may vary considerably in their referral of short children
to a paediatric endocrinologist. Moreover, endocrinologists
may vary in their decisions to initiate GHT treatment in
children with GH disorders. This variation may be driven
by patient indicators including growth pattern and average
height, or by family concern and their desire to seek medical
treatment (91). Importantly however, this variation may also
be driven by healthcare professional beliefs about the impact
of short stature and the perception of the efficacy of GHT,
particularly in children with less severe growth impairment
(91). Together, pre-determined attitudes toward GHT may
further threaten authentic SDM. While the notion of SDM
in practice is widely accepted as a preferable method over
that of a wholly paternalistic approach, there may be a
discord between this acceptance and its implementation within
the clinic.
Healthcare System-Related Barriers
Healthcare rules may be a barrier to SDM in GHT, particularly
in the context of treatment access and most specifically, device
choice. Restricted resourcing may introduce a degree of bias
associated with doctor advice and may compromise authentic
SDM with patients; cost considerations and choice of the
cheapest device may skew SDM. Resource restrictions like this
will naturally vary in their impact depending on the healthcare
system evaluated. A study by Chapman et al. investigated
the drivers of GHT prescriptions in England with respect to
price and patient preferences. This study reported only a weak
correlation between the prescription and price of GHT in
both primary and secondary care. GHT pricing was not the
predominant driver in the prescription of GH but rather the
ease of use and the number of steps required to prepare the GH
dose. Whilst restricted resourcing of healthcare systems may
be a barrier to effective SDM, this may not necessarily dissuade
doctors from offering the most suitable therapy options to their
patients, regardless of price. Despite this, healthcare systems vary
widely and the possibility for this to limit effective SDM cannot
be discounted (92).
One might also consider the implications of healthcare
payer restrictions. Grimberg et al. reported the consequences of
insurance-mandated brand switches during paediatric treatment
with GHT. Members of the Pediatric Endocrine Society were
surveyed (n = 213) and asked to reflect on their treatment
following treatment switching as determined by the healthcare
payer. Most commonly cited concerns included errors in
dosing and treatment lapses resulting from patients having
to familiarise themselves with a new GHT (93). Treatment
switches of this kind were also found to be associated with an
increase in time for the endocrine team because of additional
paperwork, educational needs, and reassurance of patients via
the telephone. Together, this study indicated that insurance-
mandated treatment switches may have a negative impact on
patient care and contribute to an increased burden on endocrine
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staff resources. These healthcare-system challenges may also
go some way to undermine opportunities for SDM given
that patient choice is ultimately overruled by healthcare payer
restrictions (93).
In a systematic review by Gravel et al. to determine commonly
cited barriers to the implementation of SDM, challenges relating
to the healthcare system that were identified also included
a lack of staff to put SDM into practice (85), insufficient
support from the healthcare organisation, inadequate access
to the services needed to put SDM into place, and insufficient
reimbursement for implementing SDM (85). Furthermore, a
study investigating the way in which general practitioners (GPs)
in the UK implemented the National Health Service (NHS)
policies of greater patient involvement, identified a willingness
to implement SDM but a disparity in its implementation given
resource restrictions (59). Some GPs viewed SDM only as
a means to improving “compliance” with treatment, rather
than as an ethical consideration, while others understood
the importance of SDM but felt there was disparity with its
interpretation in practice. These GPs also recognised that
enhanced SDM within the clinic required a greater level of
training and consultation time, both of which have financial
impact on NHS resourcing (59).
PRACTICAL SUGGESTIONS TO
OVERCOME BARRIERS TO SDM IN GHT
There are several practical solutions that may be put in place
to overcome some of the identified barriers to the effective
implementation of SDM. Primarily, education of all parties
involved in SDM is an important means by which patient
involvement in their treatment decisions may be facilitated
(Figure 2).
Patient/Parent-Related Barriers
As identified in section Barriers to the Implementation of SDM,
patient/parent-related barriers to SDM highlight a critical need
for patient education. A consensus statement on themanagement
of GH-treated adolescents in the transition to adult care details
the “education to ensure that patients have an understanding
of their disease to develop autonomy in health care decision-
making” (94). In line with this, appropriate education to better
inform patient decisions (at all ages) is of crucial importance
if SDM is to be effectively implemented and may go some way
to also positively influence treatment adherence and persistence
(45, 95).
FIGURE 2 | Solutions to overcome the barriers of SDM. GHT, growth hormone therapy; NICE, National Institute of Health and Care Excellence; SDM, shared
decision-making.
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As an example, a study by Lopez Siguero et al. reported
a disparity between patient acceptance of their treatment
and knowledge of their treatment when asked to complete a
questionnaire. Higher questionnaire scores were achieved by
patients who attended an education camp on GHT, highlighting
the benefits of appropriate patient education (96). Education is
thus important not only to enhance patient knowledge but also
to encourage a greater ownership of their own treatment plan.
Gamification technologies may also support patient education
by providing fun and interactive ways to teach patients about
their disease and the benefits of GHT (97). Gaming technologies
have been shown to promote self-management behaviour in
children with type 1 diabetes. A smartphone app developed for
patients records and rewards efforts to self-manage blood sugar
measurements and has also been shown to improve physical
activity in children (98). Additionally, application of virtual pet
technology to GHT may also encourage patient education and
promote self-management of their treatment. The virtual pet
requires care each day and in doing so, establishes a “daily play
moment” that may support adherence to GHT and may help to
decrease the anxiety that may be associated with daily injections
(97).
Consideration of the non-growth-related consequences of
GH-related disorders may also be key to engaging patients such
that they are empowered to take an active role in their treatment
journey, via the practice of SDM with their doctor. Whilst height
velocity/linear growth are the most commonly assessed measures
of treatment success in prepubertal patients, the benefits of
GHT may extend beyond improved growth. GHT is known to
have a role in body composition, lipid metabolism, androgen
action, myocardial function, and cardiovascular health, as well as,
quality-of-life perception (46). Indeed, education into the health
implications of GH-related disorders, not limited to effects on
growth must be clearly explained to patients and their families.
A patient perspective of barriers to SDM in adult patients
receiving GHT is detailed in Figure 3 and emphasises the need
for adequate education of the non-immediate and non-growth
implications of GHT. Similarly, in paediatric patients, levels of
parent anxiety may differ when confronted with reduced height
velocity as opposed to a serious GHD-related health issue and
may consequently elicit different parent responses to treatment
options.
Decision support tools are another popular tool used to aid
patient/family education and decision-making. There are several
FIGURE 3 | Barriers to the implementation of SDM—a patient perspective: GHT in adults. GHT, growth hormone therapy; IGF-1, Insulin-like growth factor-1; QoL,
quality of life; QoL-AGHDA, Quality of life assessment of growth hormone deficiency in adults; SDM, shared decision-making.
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examples of support tools that have proved effective in a variety of
therapy areas. In a meta-analysis of 105 studies that investigated
decision aid utility in 31,043 patients, decision support tools
and aids were found to increase patient knowledge, awareness
of risk factors associated with treatment and improve alignment
between personal values and the final decision made (40).
In a study to evaluate a decision aid use in cardiovascular
disease patients, patients were more encouraged to design an
action plan for their treatment and to monitor their own
progress. Indeed, 86–93% of patients rated the information in
the decision aid as “excellent” or “very good” and resulted in
an improved disease awareness and knowledge, as well as, a
more coherent understanding of personal risk factors, treatment
options and personal values (99).
Patient support groups may be another means by which
SDM is supported within the clinic. Shared experiences between
patients and their families may serve to enhance patient
confidence in their treatment regimen and facilitate a supportive
environment in which questions or concerns may be raised
and answered. Support groups for GHT patients and families
thus might help drive SDM within the clinic by providing an
educational resource during times when face-to-face contact time
FIGURE 4 | Overcoming barriers to SDM—a parent perspective: GHT in children. GHT, growth hormone therapy; SDM, shared decision-making.
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with healthcare professionals is limited. Figure 4 details a parent-
perspective of GHT in children and stresses the importance of
effective patient and parent support groups between clinic visits.
Overall, strategies to support patient education and decision-
making serve to better inform treatment plans and encourage
patients to take a more active role in their treatment journey.
While the evidence supporting the value of patient decision
aids is largely reliant on collation of data collected from patient
surveys and interviews (as dictated by the qualitative nature
of the outcomes being assessed), there is a growing body of
evidence to support the value of tools to allow patients to
consider their personal values and treatment goals so as to create
a more meaningful ownership of treatment and a confidence
in the final decisions made. If patient empowerment is the
key to treatment adherence, education is a crucial vehicle to
achieving this.
Healthcare Professional-Related Barriers
With respect to healthcare-professional barriers, training
activities to support clinicians and encourage the implementation
of SDM may be appropriate. A study by Elwyn et al. evaluated
the impact of skill development workshops for SDM and the
use of risk communication in consultation with patients. This
study reported that the level of clinician involvement in SDM
was significantly increased by attendance of skill development
workshops. Clinicians could acquire the skills they needed
to more effectively introduce SDM within their clinic and
engage patients in an active role in their treatment decisions.
Ultimately, patient involvement may be better supported by
the skill development of healthcare professionals in this area
(100). Indeed, education of all parties (not limited to the patient)
involved in SDM must be considered such that a well-informed
decision may be mutually agreed upon.
Healthcare System-Related Barriers
Healthcare system-barriers may be somewhat harder to
overcome given the financial and resourcing restrictions of
healthcare systems all over the world.
The Agency for Healthcare Research and Quality have
established the SHARE approach—a model for SDM within
the clinic (101). This five-step process aims to offer a means
by which SDM can be implemented in the clinic: S, seek
patient participation; H, help patients explore, and compare
treatment options available to them; A, assess patient values and
preferences; R, reach a decision with the patient, and E, evaluate
the patient’s decision. The SHARE approach has also established
a workshop curriculum with resources to support the training of
healthcare professionals and tools to support the implementation
of SDM within the clinic. There are also several international
groups and programmes in place to encourage the facilitation
and implementation of SDM within clinics around the world.
Many countries are involved in the International Patient Decision
Aids collaboration and have established initiatives to support
the implementation of SDM in clinical practice. Together, these
collaborations are examples of healthcare systems supporting
SDM and recognising its value in improving patient experience
of care, and ultimately patient adherence to their treatment. One
must however be aware of the challenges associated with a “one
size fits all” approach and must consider the stages in which
SDM may be most appropriate, given the subtleties of individual
patients, case specifics and healthcare system rules.
Most important to note perhaps when considering the
potential challenges to patient involvement, education is
a modifiable barrier to SDM. Whilst healthcare resource
restrictions and healthcare professional time may be harder to
overcome, an effective implementation of SDM must recognise
the opportunities for active patient involvement and seek to
modify and/or alleviate those barriers that can be tackled given
the confines/specifics of an individual patient case. Different
patients treated in different healthcare systems may dictate a very
different approach to SDM.
CONCLUSIONS
In summary, adherence to GHT is not optimal and there are
several reasons why patients may not fully adhere or persist with
their treatment regimen. A move from a clinician paternalistic
approach to a more patient autonomous approach to healthcare
has seen a greater drive to implement SDM within the clinic in
all therapy areas, not only GHT. SDM will not only ensure the
implementation of the medical ethics principles of autonomy,
beneficence, and non-maleficence, but also has been shown to
improve adherence and treatment outcomes. The scope of SDM
in the context of GHT is broad and there are several opportunities
to implement SDM within a patient journey with GHT.
It is important to consider the barriers to the implementation
of SDM and the ways one might overcome these challenges.
Finding solutions to these challenges will enable patient
empowerment and ownership of their own treatment plan and
health goals. Most importantly, education is the primary means
by which patient empowerment may be supported and must be
provided to all decision-making parties including patients, their
families and doctors. Strategies to improve education help to
inform treatment decisions, and nurture patient confidence and
satisfaction with that final decision; whatever it may be. Patient
empowerment through education in this way will encourage
improved treatment adherence, persistence and ultimately,
enhanced treatment outcomes and success.
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